drugset / Trial / NCT05887804

Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial

NCT05887804

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a double-blind randomized controlled trial (RCT) examining the effect of intralesional injection of umbilical cord-derived mesenchymal stem cells (UC-MSC), umbilical cord-derived conditioned medium (UC-CM), or triamcinolone acetonide (TA) on keloids carried out using CONSORT statement. Research is directed at studying keloid volume reduction and changes in POSAS score.

Timeline

Start
2021-10-01
Primary completion
2022-06-09
Completion
2022-06-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Acetonide Other / unclassified 40 mg/ml Other
Subject mesenchymal stem cells Cell therapy 2e+06 cells Other
Subject umbilical cord-derived mesenchymal stem cells conditioned medium Unknown 1 ml Other

Indications